BioSpace.com

Biotech and Pharmaceutical
News & Jobs
Search the Site
 
   
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login          Employers:  Register | Login  

NEWSLETTERS
Free Newsletters
Archive
My Subscriptions

NEWS
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE

CAREER NETWORK
Job Seeker Login
Most Recent Jobs
Browse Biotech Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

HOTBEDS
Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Genetown
  Pharm Country
  BioCapital
  BioMidwest
  Bio NC
  BioForest
  Southern Pharm
  BioCanada East
  US Device
Europe
Asia

DIVERSITY

INVESTOR
Market Summary
News
IPOs

PROFILES
Company Profiles

START UPS
Companies
Events

INTELLIGENCE
Research Store

INDUSTRY EVENTS
Biotech Events
Post an Event
RESOURCES
Real Estate
Business Opportunities

 News | News By Subject | News by Disease News By Date | Search News
eNewsletter Signup
Miles
Km80.5

   

Altheus Therapeutics Completes Treatment Portion Of ZA201, A Phase 2 Trial Of Zoenasa For Ulcerative Colitis


2/26/2014 11:42:55 AM

free biotech news Get the latest biotech news where you want it. Sign up for the free GenePool newsletter today!

OKLAHOMA CITY
, Feb. 26, 2014 /PRNewswire/ -- Altheus Therapeutics, Inc., announced completion of dosing in ZA201, a double-blind, active-controlled Phase 2 trial evaluating the efficacy and safety of Zoenasa® Rectal Gel versus mesalamine enema in 120 patients with left-sided ulcerative colitis.

The primary endpoint of ZA201 is reduction in the Ulcerative Colitis Disease Activity Index (UCDAI) at 6 weeks. Secondary endpoints include endoscopic remission, reduction in UCDAI at 3 weeks, and time to resolution of rectal bleeding; there are additional exploratory endpoints. Topline results will be available in April 2014.

"The ZA201 study design sets a high hurdle for Zoenasa; superiority over mesalamine standard of care. Positive results will validate the entire Zoenasa platform, so we are pleased to have achieved this critical milestone," commented Dr. Richard Harty, Founder and CSO of Altheus. "Pending positive results from ZA201, we look forward to continuing development of Zoenasa Rectal Gel and accelerating development of Zoenasa Oral Tablets."

Nearly 1.2 million Americans suffer from inflammatory bowel disease. First-line treatment for ulcerative colitis is mesalamine; however, many patients do not achieve symptomatic or endoscopic remission and must escalate to more expensive treatments that also entail greater risks.

Zoenasa is a novel combination of two FDA-approved drugs, with well-established efficacy and safety records. The combination therapy's intellectual property protection includes patents based on an unexpected synergy shown to improve the signs and symptoms of ulcerative colitis. The U.S. Food and Drug Administration has granted Zoenasa orphan drug designation for the treatment of pediatric ulcerative colitis. An oral formulation of Zoenasa is also in development.

http://clinicaltrials.gov/ct2/show/NCT01586533

About Altheus Therapeutics

Founded in 2007, Altheus Therapeutics, Inc., of Oklahoma City, OK, is a pharmaceutical development company focused on innovative therapies for the treatment of inflammatory bowel disease. http://altheustherapeutics.com.

Contact: Dennis Schafer, CEO
dschafer@altheustherapeutics.com
(405) 319-8180

SOURCE Altheus Therapeutics, Inc.



Help employers find you! Check out all the jobs and post your resume.

Read at BioSpace.com

   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES